Myriad Genetics (NASDAQ:MYGN) (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.
Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities. Myriad’s Prolaris® test evaluates prostate cancer aggressiveness by measuring gene expression levels, while its EndoPredict® assay helps predict the likelihood of breast cancer recurrence. The company also provides pharmacogenomic profiling to identify how patients may respond to certain medications, aiding in more precise drug selection and dosing.
Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad Genetics has expanded its presence internationally, serving healthcare providers in the United States, Europe, Canada, Australia and select markets in Latin America and Asia. The company operates a network of clinical laboratories and collaborates with academic institutions, biopharmaceutical firms and healthcare systems to advance genomic research and develop novel diagnostic solutions.
Under the leadership of President and Chief Executive Officer Mark C. Capone, Myriad continues to invest in research and development to broaden its test menu and drive innovation in precision medicine. The company’s strategic initiatives include expanding direct-to-physician and direct-to-consumer outreach, enhancing its data analytics capabilities and forging partnerships to integrate genetic insights into routine clinical practice.
